Diagnostics UK Market Report

Categories:, , Tag:

What the report covers

  • Market
  • Politics and regulation
  • Payors
  • Providers
  • Key suppliers to the market
  • Investors
  • Market potential
  • Appendices
  • Glossary


Who is the report for

  • Hospital & Clinic C-Suite Professionals
  • Specialist Diagnostics Providers
  • Suppliers of Imaging and Pathology Equipment
  • Private Medical Insurance Groups
  • Clinical Commissioning Groups
  • NHS Foundation Trusts
  • Professional and Trade Associations
  • Investors
  • Banks
  • Private Equity
  • Central and Local Government
  • Think Tanks
  • Lawyers
  • Management Consultants


What You Get

  • Print package – single-user Printed Hard Copy
  • Digital package – multi-user Digital PDF and Data in Excel files + Printed Hard Copy

Want to know more? Our sales team can help.

Call: 020 7841 0045
Email: [email protected]

LaingBuisson’s comprehensive study of the UK’s Diagnostics market, 1st edition. Published 11th May 2020 (261 pages).

Please contact your account manager if you are interested in our special offer for NHS and charities of £499 for a printed copy and £1,497 for a digital copy.

“Diagnostics are fundamental to the clinician’s understanding of their patient’s condition and the best treatment for them. The years between 2012 and 2018 have seen an 8-9% growth in the number of MRI and CT scans undertaken, while the number of pathology tests is growing at a rate of just over 2% per year. Given the insight that can be gained from testing and the benefits that it offers clinicians and patients alike, there is no reason to believe that when we emerge from the current crisis that this growth will not continue. While we predict continued downward pressure in pricing, demographic changes and pressure to catch up with testing rates in other counties point to sustained volume growth together with growth in the value of the market, albeit at a slower pace.

“While the trend has been away from outsourcing diagnostics from the NHS in recent years, the pressure to grow may well create further opportunities. Private imaging companies currently account for around 15% of the addressable market and diagnostics companies remain attractive to investors, reassured by the fact that payments are largely underwritten by public money. As we return to normal after Coronavirus, there is no reason to think that the UK diagnostics market will not return in time to the growth trajectory on which it was set prior to March 2020.”

                                                                                                                                                Hugh Risebrow, report author

The first edition of LaingBuisson’s Diagnostics UK Market Report offers a picture of a high value and growing market which makes it highly attractive to investors. While the current crisis will undoubtedly change the market’s focus for the short-term, understanding its underlying dynamics and potential makes this report vital reading for investors, advisors, suppliers, commissioners and providers to the UK diagnostics market.


has been added to the cart. View Cart